These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 16339684

  • 1. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S, Tang H, Jensen JH, Altmann K, Prakash A, Printz BF, Hordof AJ, Tosti CL, Azabagic A, Swaminathan S, Brown TR, Olivieri NF, Brittenham GM.
    Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
    [Abstract] [Full Text] [Related]

  • 2. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
    Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ.
    Toxicol Mech Methods; 2013 Jan; 23(1):48-56. PubMed ID: 22943064
    [Abstract] [Full Text] [Related]

  • 3. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 4. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients.
    Taher AT, Musallam KM, Wood JC, Cappellini MD.
    Am J Hematol; 2010 Apr 10; 85(4):288-90. PubMed ID: 20143405
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/beta-thalassaemia.
    Ghoti H, Goitein O, Koren A, Levin C, Kushnir T, Rachmilewitz E, Konen E.
    Eur J Haematol; 2010 Jan 01; 84(1):59-63. PubMed ID: 19793250
    [Abstract] [Full Text] [Related]

  • 10. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
    Inati A, Musallam KM, Wood JC, Sheikh-Taha M, Daou L, Taher AT.
    Eur J Haematol; 2009 Dec 01; 83(6):565-71. PubMed ID: 19737308
    [Abstract] [Full Text] [Related]

  • 11. The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients.
    Kolnagou A, Michaelides Y, Kontoghiorghe CN, Kontoghiorghes GJ.
    Toxicol Mech Methods; 2013 Jan 01; 23(1):34-41. PubMed ID: 23039902
    [Abstract] [Full Text] [Related]

  • 12. Assessmrent of iron overload in thalassaemic patients by magnetic resonance imaging: a pilot study.
    Kumar P, Jagannathan NR, Choudhry VP.
    J Indian Med Assoc; 2007 Oct 01; 105(10):561-4, 591. PubMed ID: 18383951
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
    Origa R, Danjou F, Cossa S, Matta G, Bina P, Dessì C, Defraia E, Foschini ML, Leoni G, Morittu M, Galanello R.
    Br J Haematol; 2013 Nov 01; 163(3):400-3. PubMed ID: 24033185
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ.
    Ann N Y Acad Sci; 2005 Nov 01; 1054():373-8. PubMed ID: 16339685
    [Abstract] [Full Text] [Related]

  • 17. Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients.
    Rose C, Vandevenne P, Bourgeois E, Cambier N, Ernst O.
    Eur J Haematol; 2006 Aug 01; 77(2):145-9. PubMed ID: 16608501
    [Abstract] [Full Text] [Related]

  • 18. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Aug 01; 1054():486-91. PubMed ID: 16339703
    [Abstract] [Full Text] [Related]

  • 19. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Aug 01; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 20. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload.
    Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M.
    J Magn Reson Imaging; 2006 May 01; 23(5):662-8. PubMed ID: 16568436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.